Glucagon Like Peptide 1 Receptor Agonists and Dual Glucose Dependent Insulinotropic Polypeptide Glucagon Like Peptide 1 Receptor Agonists in the Treatment of Obesity Metabolic Syndrome, Prediabetes Diabetes and Non Alcoholic Fatty Liver DiseaseCurrent GLP 1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add on Value of a Combined Therapy Drugs Springer Nature Link The evolving story of incretins (GIP and GLP1) in metabolic and cardiovascular disease: A pathophysiological update Nauck 2021 Diabetes, Obesity and Metabolism Wiley Online Library Glucagon like peptide 1 receptor: mechanisms and advances in therapy Signal Transduction and Targeted Therapy Nutritional priorities to support GLP 1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society